- Research article
- Open Access
- Open Peer Review
Destructive impact of t-lymphocytes, NK and mast cells on basal cell layers: implications for tumor invasion
- Hongyan Yuan†1Email author,
- Yi-Hsuan Hsiao†2, 3,
- Yiyu Zhang4,
- Jinlian Wang5,
- Chao Yin6,
- Rong Shen1Email author and
- Yiping Su1Email author
© Yuan et al.; licensee BioMed Central Ltd. 2013
- Received: 27 December 2012
- Accepted: 14 May 2013
- Published: 25 May 2013
Our previous studies have suggested that the primary impact of immune cell infiltration into the normal or pre-invasive tissue component is associated with the physical destruction of epithelial capsules, which may promote tumor progression and invasion. Our current study attempted to further verify our previous observations and determine the primary type(s) of infiltrating immune cells and the possible mechanism associated with physical destructions of the epithelial capsules.
In total, the study was conducted with 250 primary breast and prostate tumors, the primary immune cell of cytotoxic T-lymphocytes (CTL), Natural killer cells (NK) and Mast cells were analyzed by immunohistochemistry, fluorescent labeling and apoptosis assay. qRT-PCR was used for gene expression analysis. Our current study assessed the physical disruption of these immune cells and potential impact on the epithelial capsule of human breast and prostate tumors.
Our study yield several clinically-relevant findings that have not been studied before. (1) A vast majority of these infiltrating immune cells are distributed in the normal-appearing or pre-invasive tissue components rather than in invasive cancer tissues. (2) These cells often form rings or semilunar structures that either surround focally-disrupted basal cell layers or physically attach to the basal cells. (3) Basal cells physically associated with these immune cells generally displayed distinct signs of degeneration, including substantially elevated apoptosis, necrosis, and reduced tumor suppressor p63 expression. In contrast, luminal cells overlying focally disrupted basal cell layers had a substantially increased proliferation rate and elevated expression of stem cell markers compared to their adjacent morphologically similar counterparts that overlie a non-disrupted capsule.
Our findings suggest that at the early stage of tumor invasion, CTL, NK and Mast cells are the main types of tumor infiltrating immune cells involved in focal degenerative products in the tumor capsules. The primary impact of these infiltrating immune cells is that they are associated with focal disruptions of the tumor capsule, which selectively favor tumor stem cells proliferation and invasion.
- Immune cells
The impact and clinical significance of tumor-infiltrating immune cells remain a hot topic after decade of debate. A large number of publications have reported that the direct physical contact between infiltrated immune cells and tumor cells is associated with the physical destruction of associated tumor cells, reduction of the tumor size, and significantly improved clinical prognoses [1–6]. However, an increasing number of publications show that increased infiltration of immune cells may promote tumor progression and invasion. Previous reports that stage and histopathologically matched pre-invasive prostate and esophageal tumors with increased immune cell infiltration have a significantly higher frequency of subsequent progression to invasive lesions, compared to their counterparts without immune cell infiltration [7–9]. It has also been reported: (a) macrophages can enhance cancer cell migration through secretion of chemotactic and chemokinetic factors that promote fibrillogenesis and angiogenesis, allowing tumor cells to track along collagen fibers and blood vessels [10, 11], (b) macrophages ingest tumor cells induce a mixture of genetic materials and create a hybrid phenotype which can metastasize to remote sites to form new colonies , (c) T-lymphocytes promote invasion and metastasis by regulating tumor-associated macrophages ; (d) infiltration of immune cells can export growth factors and other proliferation-related molecules to associated tumor cells through direct physical contact and promote epithelial-mesenchymal transition (EMT) and cell motility [14, 15].
The contradictory observations regarding the impact of tumor-infiltrating immune cells have caused confusions in judging the clinical implications of aberrant infiltration of immune cells within tumor tissues. In addition, as immune cell-mediated lysis or cytotoxic assays are almost exclusively conducted on cell cultures or animal models, these in vitro assays cannot fully mimic the intrinsic events in human carcinogenesis [16–18]. It has been well documented that the immune-surveillance systems differ significantly in human and animals [19, 20].
We have speculated that these contradictory reports and statements may result from different tumor stages, in which infiltrating immune cells may be associated with differential consequences depending on the cell type. To validate our speculation, our previous studies compared the pattern and frequency of physical association of tumor-infiltrating immune cells with basal and luminal cells of breast and prostate tumors that harbor both pre-invasive and invasive components. Our studies revealed that: (1) over 90% of infiltrating immune cells were distributed in the normal or pre-invasive tissue component, while fewer than 10% were in the invasive tissue component, (2) within the normal or pre-invasive tissue component, over 90% of the epithelial structures with a focally disrupted epithelial capsule were associated with infiltrating immune cells, compared to about 30% in epithelial structures with a non-disrupted capsule, (3) a vast majority of infiltrating immune cells were located on or near the site of focally disrupted epithelial capsules, and (4) epithelial cells overlying focally disrupted capsules often show a substantially increased proliferation rate and often form finger- or tongue-like projections invading the adjacent stroma [21–25]. Based on these and other findings, we have hypothesized that the primary impact of immune cell infiltration into normal or pre-invasive tissue component is the physical destruction of epithelial capsules, which may promote tumor progression and invasion [26, 27].
Our current study attempted to further verify our previous observations and determine the primary type(s) of infiltrating immune cells and the possible mechanism(s) associated with physical destructions of the epithelial capsules. As it has been well documented that: (1) CTL, natural killer (NK) and Mast cells are the primary immune cell types for detecting and eliminating degenerated and altered host cells and (2) these three cell types harbor similar cytotoxic granules and share the same mechanism for the exocytosis of their granules [28–31], we have hypothesized they may be preferentially localized on degenerated basal cell layers and function coordinately in the physical destruction of degenerated epithelial capsules.
Formalin-fixed, paraffin-embedded human breast tissue (N = 150) were retrieved from the files of the Department of Pathology and Department of Oncology, the Affiliated Nanjing Maternity and Child Health Care Hospital, Nanjing Medical University. Human prostate (N = 100) tumor tissue blocks were obtained from Department of Pathology, Affiliated Jiangsu people’s hospital, Nanjing Medical University with an IRB approval from Nanjing Medical University.
Serial 5-7 μm sections were made from the breast and prostate tumor tissue blocks. The first and last sections from each block were stained with Hematoxylin & Eosin (H&E) for morphological classification using published criteria. Double immunohistochemistry was applied to assess the potential impact of infiltrating immune cells on other cell types and structures using previously published protocol . The secondary antibody, ABC detection kit and diaminobenzidine chromogen kit were obtained from Vector Laboratories (Burlingame, CA, USA). The AP red-chromogen kit was purchased from Zymad Laboratories (South San Francisco, CA, USA). Negative control slides (IgG only) were included in each individual analysis.
Immune cell aggregates and tumor infiltrating immune cells were elucidated with leukocyte common antigen (LCA, clone: 2B11 + PD7/26; Dako, Carpinteria, CA, USA), CD8 (clone: C8144B), CD16 (clone: DJ130c) and Mast cell tryptase (clone: AA1) (Dako). The breast myoepithelial and prostate basal cells were identified with smooth muscle actin (SMA; clone: 1A4; Sigma, USA) and cytokeratin (CK34βE12 (clone: M0630; Dako) respectively. The focal capsule disruptions were defined as the presence of a physical gap in a given myoepithelial or basal cell layer that is larger than the combined size of at least three epithelial cells and in at least three consecutive sections. Physical signs of degeneration-related changes were defined as the loss of expression of phenotypic markers, vacuolation, fragmentation, swelling, nuclear membrane breakage, chromatin condensation, atrophy, and necrosis. To assess the potential impact of physical association between infiltrated immune cells and basal or luminal cells, immunostained sections and photographs were independently reviewed by three investigators. A given cell was considered immunoreactive if distinct immunoreactivity was consistently present in its cytoplasm, membrane or nucleus while absent in all negative controls. All infiltrated immune cell aggregates in each case were counted, the frequencies of these aggregates within pre-invasive and invasive tissue components were statistically compared by the Pearson’s Chi-square test. To compare the frequencies of cytological signs of degeneration in basal and luminal cells that are physically associated with infiltrated immune cells, digital images were taken in 3–5 randomly selected basal cell layers and associated luminal cells subjacent to or surrounded by infiltrated immune-cells. Digital images were enlarged and viewed on a computer to detect potential signs of degeneration defined as above. The total numbers of cells counted and cells with cytological signs of degeneration in each group were added and averaged, the averaged frequencies were statistically compared by the Pearson’s Chi-square test. Statistical significance was defined as p < 0.05.
Apoptosis assay. Tissue sections from 10 cases with a high frequency of degeneration-related changes in the basal cell layers were subjected to apoptosis detection with Apoptosis Detection Kit (CHEMICON International, USA) according to the manufacturer’ protocol. After wash, the sections were staining for CK34βE12 to determine the histological origin of apoptotic cells.
The expression status of tumor suppressor p63 in the basal cell layers: p63 expression in basal cells within non-disrupted and focally disrupted residual layers were compared by double immunostaining of CK34βE12 and p63. To verify the sub-cellular localization of basal cell phenotypic makers CK34βE12 and p63, sets of adjacent human prostate tissue sections from 10 selected cases were double immunostained for CK34βE12 and p63 (clone: 4A4; Cell Marque, Rocklin, CA, USA). The antigen-antibody complexes were distinguished by different secondary antibodies labeled with different fluorophores (DyLight 488 and Dylight 549; KPL, Gaithersburg, MD, USA) according to the manufacturer’s instructions. Immunostained sections were examined and digital images were taken in a fluorescent microscope (Fluoview 300; Olympus America, Inc., Center Valley, PA, USA).
Proliferation index and lymphatic duct density: To further assess the potential impact of infiltrating immune cells on cell proliferation and angiogenesis, tissue sections from 30-selected cases were double immunostained for CK34βE12 and a cell proliferation marker, Ki-67 (clone: MM1; Dako). The proliferation status in epithelial cells surrounded by infiltrating immune cells were compared to those cells that were distant from infiltrating immune cells. In addition, special attention was paid to identify whether proliferating cells were preferentially located on the site of focally disrupted basal cell layers.
Microdisection and Quantitative Real-Time PCR (qRT-PCR): Five unstained adjacent sections or immunostained sections with pre-invasive tumors showing extensive focal capsule disruptions and immune cell infiltration were deparaffinized and lightly stained with hematoxylin. Guided by immunostained sections, morphologically similar pre-invasive lesions with and without extensive focal capsule disruptions and immune cell infiltration were microdissected and subjected to RNA extraction by RNeasy FFPE Kit (Qiagen) according to the manufacturer’s instructions. Total RNA (0.5 μg) was reverse transcribed in a total volume of 20 μl using the Omniscript RT kit (Qiagen). Quantitative PCR was performed in triplicate in an ABI-Prism 7700 instrument (Applied Biosystems, Foster City, CA,USA) using QuantiTect Sybr green (Qiagen, Gaithersberg, MD, USA) according to the manufacturer’s protocol. The appropriate primer sets were listed in Additional file 1: Table S1. Amplification was confirmed by ethidium bromide staining of the PCR products on a 2% agarose gel. The expression of each target gene was based on five pooled samples, and normalized by GAPDH RNA expression, expressed as 2-ΔCt, where Ct is the threshold cycle and ΔCt = CtTarget - Ct GAPDH.
Student’s test was performed for two group comparisons. The data presented represent mean ± SEM. P-value of less than 0.05 was considered to be statistically significant.
The sub-cellular localization and cell types that reacted to the antibodies were consistent with those of published data and specifications of manufactures. All negative controls were consistently devoid of distinct immunoreactivity. The results were highly consistent in duplicates or triplicates. The basal and luminal cells were distinguishable by morphology and by immunohistochemistry in all study cases. The basal cell population is characterized by its spindle or elongated shape with densely stained nucleus, CK34βE12 staining in the cytoplasm, and p63 staining in nucleus. The luminal cell population is characterized by its round or oval shape with lightly stained nucleus harboring distinct nucleoli. It is devoid of CK34βE12 and p63 expression. CD16, CD56, Fox3p, Mast, and neutrophils cells are primarily known as lymphocytes; thus, they have been collectively referred as infiltrated lymphocytes below. Both the prostate basal and breast myoepithelial cells are referred to as basal cells below.
Distribution of lymphocyte aggregates
Number of aggregates
Invasive cancer component
Focally disrupted capsules
The preferential association of tumor-infiltrating lymphocytes with the basal cell population appears to result primarily from focal degeneration and disruption of the basal cell layers. Our previous studies have consistently shown that compared to its morphologically clear-cut and undisrupted counterpart, a focally disrupted basal cell layer has significantly lower expressions of tumor suppressor p63 and proliferating cell nuclear antigen, while it has significantly higher frequencies of apoptosis and degeneration . As shown in Figures 8 and 9, a vast majority of the basal cells within undisrupted layers express both CK34βE12 and p63, while most basal cells within disrupted layers lack p63 expression with distinct signs of degeneration. Thus, it is very likely that the basal cells in these patients may belong to an “aged” or degenerated population, and that the degradation products of these basal cells may function as self-epitopes to stimulate the production of auto-antibodies or to attract the migration and infiltration of immune cells. Consistent with our speculation, our recent study has revealed that protease-degraded collagen I fragments of the breast tumor capsule function as a specific mediator to attract macrophage and other immune cell infiltration .
As the breast and prostate epithelium is normally devoid of both blood vessels and lymphatic ducts and the my epithelial or basal cell layer is the sole source of several tumor suppressors [35–37], a focal degeneration or disruption in a given basal cell layer could cause direct exposure of tumor cells to the tumor microenvirment complexity, and lead to several focal alterations with significant consequences, including: (a) local loss of tumor suppressors and paracrine inhibitory functions, which confer epithelial cell growth advantages allowing them to escape from programmed cell death ; ( b) local increase of immune cells infiltration, could increase of permeability to oxygen, nutrients, and growth factors, which selectively favors the proliferation of progenitor/stem cells [39, 40]; (c) direct epithelial stromal cell contact, which augments the expression of stromal matrix metalloproteinase (MMP) or other cell adhesion molecules , which facilitate epithelial to mesenchymal transition (EMT) and cell motility ; (d) direct exposure of the epithelial cells to different cytokines, which facilitates vasculogenic mimicry and tumor angiogenesis , and (e) direct physical contact between newly formed cell clusters and stromal cells, which stimulates the production of tenascin and other host factors such as hepatocyte growth factor(HGF) that facilitate stromal tissue remodeling and drug resisiance [43–45]. These alterations can individually or synchronously increase proliferation and motility in cells overlying such disruptions. Thus, tumor cell clusters overlying focally disrupted capsules are very likely to represent a population of tumor progenitors with a greater propensity to progress to invasive or metastatic cancer. CD133 and ly6E have been reported as tumor-initiating cells (TIC) markers for breast cancer and pancreatic Cancer [46, 47], Nanog and Sox2 are ES cell markers that have been reported in poorly differentiated breast cancer, and correlated with poor survival . Elevated expression of stem cell markers in pre-invasive tumors with extensive focal capsule disruptions and immune cell infiltration suggests that focal capsule disruptions and immune cell infiltration may stimulate or facilitate the exit of stem cells from quiescence, allowing the stem cells to undergo proliferation and invasion into the adjacent stroma or vascular structures.
Our recent studies have consistently revealed that 15-30% of the patients with non-invasive breast or prostate tumors harbor epithelial structures that are morphologically normal or hyperplastic in H&E stained sections, but they show frequent focal capsule disruptions with budding cells in immunohistochemically stained sections [26–31]. The intrinsic entity of these structures is unknown, but they most likely represent a previously undefined malignant phenotype, or the direct precursor of malignant lesions. Our results are consistent with several lines of evidence: (1) mammary ductal intraepithelial neoplasia (DIN)-flat type is a subtle epithelial alteration characterized by one or a few layer(s) of atypical cells replacing the native epithelium, but loss of heterozygosity (LOH) was detected in 17 of 22 (77%) lesions, and monoclonality was established in the 2 cases analyzed ; (2) LOH was detected in morphologically normal lobules adjacent to breast cancers. In 10 cases with LOH at chromosome 3p22-25 in the carcinoma, 6 displayed the same LOH in adjacent normal lobules , and (3) the prostate tissues in a subset of aged men or normal-appearing prostate tissues adjacent to prostate cancer harbored a DNA phenotype that is identical to invasive and metastasized prostate cancer [51–53]. Together, these findings suggest that those morphologically normal or hyperplastic appearing breast and prostate epithelial structures may have accumulated significant genetic abnormalities, which suggests an early stage of malignant transformation or an increased risk for invasive or metastatic lesions.
The infiltrated host immune cell classification in combine with some other marker may have a prognostic value for tumor invasion and metastasis . As the disruption of the tumor capsule is an absolute prerequisite for tumor invasion and metastasis, our hypothesis, if confirmed, is likely to have significant scientific implications and clinical applications. Furthermore, the elucidation of the molecular profiles of the cell population overlying focal capsule disruptions may lead to the identification of clinically relevant surrogate biomarkers that can be used to distinguish between clinically aggressive and indolent pre-invasive tumors.
Our current study in breast and prostate tumors has revealed: (1) 154 total lymphocyte aggregates detected were preferentially associated with pre-invasive structures that have focally disrupted capsules; (2) infiltrated lymphocytes were predominantly seen at the site of focally disrupted tumor capsules; (3) a vast majority of the basal cells were immediately subjacent to or physically associated with infiltrating lymphocytes and displayed a wide variety of cytological signs of degeneration; and (4) focal tumor capsule disruptions coupled with lymphocyte infiltration with the stem cell signature appear to facilitate proliferation and dissociation of the overlying luminal cells. Together, our findings are consistent with our hypothesis: tumor-infiltrating lymphocytes are exclusively or preferentially associated with degenerated basal cells in the initial or early stage of tumor invasion. To our knowledge, this is the first report, which suggests that the primary impact of tumor infiltrating CTL, NK and Mast cells may be associated with the physical disruptions of the tumor capsule. In addition, our findings could offer a reasonable explanation for the contradictory reports and statements regarding the impact and clinical significance of immune cell infiltration into tumor tissues.
We appreciate Dr. Xirong Guo for giving comments to the manuscript. Dr. Yan-gao Man has contributed substantially scientific concept of the role of immune cells in promoting tumor invasion, and assists to construct the manuscript. This work was supported by grant SKLRM-KF-1206 from State Key Laboratory of Reproductive Medicine and by grant 200901083 from Nanjing Science and Technology foundation, Nanjing, China. The funders were not involved in experiments design, data collection & analysis and manuscript writing.
- Baxevanis CN, Dedoussis GV, Papadopoulos NG, Missitzis I, Stathopoulos GP, Papamichail M: Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer. Cancer. 1994, 74 (4): 1275-1282. 10.1002/1097-0142(19940815)74:4<1275::AID-CNCR2820740416>3.0.CO;2-Q.View ArticlePubMedGoogle Scholar
- Boon T, Coulie PG, Van den Eynde B: Tumor antigens recognized by T cells. Immunol Today. 1997, 18 (6): 267-268.View ArticlePubMedGoogle Scholar
- Van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991, 254 (5038): 1643-1647. 10.1126/science.1840703.View ArticlePubMedGoogle Scholar
- Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M, Meyerhardt JA, Giovannucci E, Dranoff G, Fuchs CS, Ogino S: Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol. 2010, 222 (4): 350-366. 10.1002/path.2774.View ArticlePubMedPubMed CentralGoogle Scholar
- Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, et al: Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005, 353 (25): 2654-2666. 10.1056/NEJMoa051424.View ArticlePubMedGoogle Scholar
- Suzuki H, Chikazawa N, Tasaka T, Wada J, Yamasaki A, Kitaura Y, Sozaki M, Tanaka M, Onishi H, Morisaki T, et al: Intratumoral CD8(+) T/FOXP3 (+) cell ratio is a predictive marker for survival in patients with colorectal cancer. Cancer Immunol Immunother. 2010, 59 (5): 653-661. 10.1007/s00262-009-0781-9.View ArticlePubMedGoogle Scholar
- Gannot G, Gannot I, Vered H, Buchner A, Keisari Y: Increase in immune cell infiltration with progression of oral epithelium from hyperkeratosis to dysplasia and carcinoma. Br J Cancer. 2002, 86 (9): 1444-1448. 10.1038/sj.bjc.6600282.View ArticlePubMedPubMed CentralGoogle Scholar
- MacLennan GT, Eisenberg R, Fleshman RL, Taylor JM, Fu P, Resnick MI, Gupta S: The influence of chronic inflammation in prostatic carcinogenesis: a 5-year followup study. J Urol. 2006, 176 (3): 1012-1016. 10.1016/j.juro.2006.04.033.View ArticlePubMedGoogle Scholar
- Smith CJ, Gardner WA: Inflammation-proliferation: possible relationships in the prostate. Prog Clin Biol Res. 1987, 239: 317-325.PubMedGoogle Scholar
- Pollard JW: Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004, 4 (1): 71-78. 10.1038/nrc1256.View ArticlePubMedGoogle Scholar
- Wyckoff J, Wang W, Lin EY, Wang Y, Pixley F, Stanley ER, Graf T, Pollard JW, Segall J, Condeelis J: A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res. 2004, 64 (19): 7022-7029. 10.1158/0008-5472.CAN-04-1449.View ArticlePubMedGoogle Scholar
- Pawelek JM, Chakraborty AK: The cancer cell–leukocyte fusion theory of metastasis. Adv Cancer Res. 2008, 101: 397-444.View ArticlePubMedGoogle Scholar
- DeNardo DG, Johansson M, Coussens LM: Immune cells as mediators of solid tumor metastasis. Cancer Metastasis Rev. 2008, 27 (1): 11-18. 10.1007/s10555-007-9100-0.View ArticlePubMedGoogle Scholar
- Hunter KW, Crawford NP, Alsarraj J: Mechanisms of metastasis. Breast Cancer Res. 2008, 10 Suppl (1): S2-View ArticleGoogle Scholar
- Nauseef JT, Henry MD: Epithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle?. Nat Rev Urol. 2011, 8 (8): 428-439. 10.1038/nrurol.2011.85.View ArticlePubMedGoogle Scholar
- Kuppen PJ, Gorter A, Hagenaars M, Jonges LE, Giezeman-Smits KM, Nagelkerke JF, Fleuren G, Van de Velde CJ: Role of NK cells in adoptive immunotherapy of metastatic colorectal cancer in a syngeneic rat model. Immunol Rev. 2001, 184: 236-243. 10.1034/j.1600-065x.2001.1840121.x.View ArticlePubMedGoogle Scholar
- Liu KJ, Wang CJ, Chang CJ, Hu HI, Hsu PJ, Wu YC, Bai CH, Sytwu HK, Yen BL: Surface expression of HLA-G is involved in mediating immunomodulatory effects of placenta-derived multipotent cells (PDMCs) towards natural killer lymphocytes. Cell Transplant. 2011, 20 (11–12): 1721-1730.View ArticlePubMedGoogle Scholar
- Fishman M, Gunther G: Induction of tumor cell resistance to macrophagemediated lysis by preexposure to non-activated macrophages. Cell Immunol. 1986, 99 (1): 241-256. 10.1016/0008-8749(86)90232-7.View ArticlePubMedGoogle Scholar
- Kovacs EJ, Palmer JL, Fortin CF, Fulop T, Goldstein DR, Linton PJ: Aging and innate immunity in the mouse: impact of intrinsic and extrinsic factors. Trends Immunol. 2009, 30 (7): 319-324. 10.1016/j.it.2009.03.012.View ArticlePubMedPubMed CentralGoogle Scholar
- Padgett EL, Pruett SB: Rat, mouse and human neutrophils stimulated by a variety of activating agents produce much less nitrite than rodent macrophages. Immunology. 1995, 84 (1): 135-141.PubMedPubMed CentralGoogle Scholar
- Man YG, Shen T, Zhao Y, Amy Sang QX: Focal prostate basal cell layer disruptions and leukocyte infiltration are correlated events: A potential mechanism for basal cell layer disruptions and tumor invasion. Cancer Detect Prev. 2005, 29 (2): 161-169. 10.1016/j.cdp.2005.01.004.View ArticlePubMedGoogle Scholar
- Yousefi M, Mattu R, Gao C, Man YG: Mammary ducts with and without focal myoepithelial cell layer disruptions show a different frequency of white blood cell infiltration and growth pattern: implications for tumor progression and invasion. Appl Immunohistochem Mol Morphol. 2005, 13 (1): 30-37. 10.1097/00129039-200503000-00006.View ArticlePubMedGoogle Scholar
- Man YG, Tai L, Barner R, Vang R, Saenger JS, Shekitka KM, Bratthauer GL, Wheeler DT, Liang CY, Vinh TN, et al: Cell clusters overlying focally disrupted mammary myoepithelial cell layers and adjacent cells within the same duct display different immunohistochemical and genetic features: implications for tumor progression and invasion. Breast Cancer Res. 2003, 5 (6): R231-R241. 10.1186/bcr653.View ArticlePubMedPubMed CentralGoogle Scholar
- Man YG, Zhang Y, Shen T, Zeng X, Tauler J, Mulshine JL, Strauss BL: cDNA expression profiling reveals elevated gene expression in cell clusters overlying focally disrupted myoepithelial cell layers: implications for breast tumor invasion. Breast Cancer Res Treat. 2005, 89 (2): 199-208. 10.1007/s10549-004-2049-6.View ArticlePubMedGoogle Scholar
- Man YGZC, Wang J: Breast tumor cell clusters and their budding derivatives show different immunohistochemical profiles during stromal invasion: implications for hormonal and drug therapies. Cancer Therapy. 2006, 4: 193-204.Google Scholar
- Man YG: Focal degeneration of aged or injured myoepithelial cells and the resultant auto-immunoreactions are trigger factors for breast tumor invasion. Med Hypotheses. 2007, 69 (6): 1340-1357. 10.1016/j.mehy.2007.02.031.View ArticlePubMedGoogle Scholar
- Man YG, Gardner WA: Focal degeneration of basal cells and the resultant auto-immunoreactions: a novel mechanism for prostate tumor progression and invasion. Med Hypotheses. 2008, 70 (2): 387-408. 10.1016/j.mehy.2007.05.015.View ArticlePubMedGoogle Scholar
- Cullen SP, Brunet M, Martin SJ: Granzymes in cancer and immunity. Cell Death Differ. 2010, 17 (4): 616-623. 10.1038/cdd.2009.206.View ArticlePubMedGoogle Scholar
- Topham NJ, Hewitt EW: Natural killer cell cytotoxicity: how do they pull the trigger?. Immunology. 2009, 128 (1): 7-15. 10.1111/j.1365-2567.2009.03123.x.View ArticlePubMedPubMed CentralGoogle Scholar
- Waterhouse NJ, Clarke CJ, Sedelies KA, Teng MW, Trapani JA: Cytotoxic lymphocytes; instigators of dramatic target cell death. Biochem Pharmacol. 2004, 68 (6): 1033-1040. 10.1016/j.bcp.2004.05.043.View ArticlePubMedGoogle Scholar
- De Saint BG, Menasche G, Fischer A: Molecular mechanisms of biogenesis and exocytosis of cytotoxic granules. Nat Rev Immunol. 2010, 10 (8): 568-579. 10.1038/nri2803.View ArticleGoogle Scholar
- Man YG, Burgar A: An antigen unmasking protocol that satisfies both immunohistochemistry and subsequent PCR amplification. Pathol Res Pract. 2003, 199: 815-825. 10.1078/0344-0338-00501.View ArticlePubMedGoogle Scholar
- Hsiao YH, Su YA, Tsai HD, Mason JT, Chou MC, Man YG: Increased invasiveness and aggressiveness in breast epithelia with cytoplasmic p63 expression. Int J Biol Sci. 2010, 6 (5): 428-442.View ArticlePubMedPubMed CentralGoogle Scholar
- O'Brien J, Lyons T, Monks J, Lucia MS, Wilson RS, Hines L, Man YG, Borges V, Schedin P: Alternatively activated macrophages and collagen remodeling characterize the postpartum involuting mammary gland across species. Am J Pathol. 2010, 176 (3): 1241-1255. 10.2353/ajpath.2010.090735.View ArticlePubMedPubMed CentralGoogle Scholar
- Man YG: A seemingly most effective target for early detection and intervention of prostate tumor invasion. J Cancer. 2010, 24 (1): 63-69.View ArticleGoogle Scholar
- Pires MM, Hopkins BD, Saal LH, Parsons RE: Alterations of EGFR, p53 and PTEN that mimic changes found in basal-like breast cancer promote transformation of human mammary epithelial cells. Cancer Biol Ther. 2013, 14 (3): 246-253. 10.4161/cbt.23297.View ArticlePubMedPubMed CentralGoogle Scholar
- Brimo F, Epstein JI: Immunohistochemical pitfalls in prostate pathology. Hum Pathol. 2012, 43 (3): 313-324. 10.1016/j.humpath.2011.11.005.View ArticlePubMedGoogle Scholar
- Man YG, Stojadinovic A, Mason J, Avital I, Bilchik A, Bruecher B, Protic M, Nissan A, Izadjoo M, Zhang X, Jewett A: Tumor-infiltrating immune cells promoting tumor invasion and metastasis: existing theories. J Cancer. 2013, 4 (1): 84-95. 10.7150/jca.5482.View ArticlePubMedPubMed CentralGoogle Scholar
- Ogino S, Galon J, Fuchs CS, Dranoff G: Cancer immunology-analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol. 2011, 8 (12): 711-719. 10.1038/nrclinonc.2011.122.View ArticlePubMedPubMed CentralGoogle Scholar
- Ilunga K, Nishiura R, Inada H, El-Karef A, Imanaka-Yoshida K, Sakakura T, Yoshida T: Co-stimulation of human breast cancer cells with transforming growth factor-beta and tenasicin-c enhances matrix metalloproteinase-9 expression and cancer cell invasion. Int J Exp Pathol. 2004, 85: 373-379. 10.1111/j.0959-9673.2004.00406.x.View ArticlePubMedPubMed CentralGoogle Scholar
- Kryczka J, Stasiak M, Dziki L, Mik M, Dziki A, Cierniewski C: Matrix metalloproteinase-2 cleavage of the β1 integrin ectodomain facilitates colon cancer cell motility. J Biol Chem. 2012, 287 (43): 36556-36566. 10.1074/jbc.M112.384909.View ArticlePubMedPubMed CentralGoogle Scholar
- Yoshimura A: Signal transduction of inflammatory cytokines and tumor development. Cancer Sci. 2006, 97 (6): 439-447. 10.1111/j.1349-7006.2006.00197.x.View ArticlePubMedGoogle Scholar
- Midwood KS, Orend G: The role of tenascin-C in tissue injury and tumorigenesis. J Cell Commun Signal. 2009, 3 (3–4): 287-310.View ArticlePubMedPubMed CentralGoogle Scholar
- Verstraeten AA, Mackie EJ, Hageman PC, Hilgers J, Schol DJ, De Jongh GJ, Schalkwijk J: Tenascin expression in basal cell carcinoma. Brit J Dermt. 1992, 127: 571-574. 10.1111/j.1365-2133.1992.tb14867.x.View ArticleGoogle Scholar
- Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J, Frederick DT, Cooper ZA, Chapman PB, Solit DB, Ribas A, Lo RS, Flaherty KT, Ogino S, Wargo JA, Golub TR: Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012, 487 (7408): 500-504. 10.1038/nature11183.View ArticlePubMedPubMed CentralGoogle Scholar
- Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV, Varticovski LJ: Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res. 2008, 10 (1): R10-10.1186/bcr1855.View ArticlePubMedPubMed CentralGoogle Scholar
- Gou S, Liu T, Wang C, Yin T, Li K, Yang M, Zhou J: Establishment of clonal colony-forming assay for propagation of pancreatic cancer cells with stem cell properties. Pancreas. 2007, 34: 429-435. 10.1097/MPA.0b013e318033f9f4.View ArticlePubMedGoogle Scholar
- Ben-Porath I, Thomson MW, Carey VJ, Gxxe R, Bell GW, Regev A, Weinberg RA: An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet. 2008, 40: 499-507. 10.1038/ng.127.View ArticlePubMedPubMed CentralGoogle Scholar
- Moinfar F, Man YG, Bratthauer GL, Ratschek M, Tavassoli FA: Genetic abnormalities in mammary ductal intraepithelial neoplasia-flat type (“clinging ductal carcinoma in situ”): a simulator of normal mammary epithelium. Cancer. 2000, 88 (9): 2072-2081. 10.1002/(SICI)1097-0142(20000501)88:9<2072::AID-CNCR13>3.0.CO;2-H.View ArticlePubMedGoogle Scholar
- Deng G, Lu Y, Zlotnikov G, Thor AD, Smith HS: Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science. 1997, 274 (5295): 2057-2059.View ArticleGoogle Scholar
- Malins DC, Gilman NK, Green VM, Wheeler TM, Barker EA, Vinson MA, Sayeeduddin M, Hellström KE, Anderson KM: Metastatic cancer DNA phenotype identified in normal tissues surrounding metastasizing prostate carcinomas. Proc Natl Acad Sci. 2004, 101: 11428-11431. 10.1073/pnas.0404572101.View ArticlePubMedPubMed CentralGoogle Scholar
- Malins DC, Anderson KM, Gilman NK, Green VM, Barker EA, Hellström KE: Development of a cancer DNA phenotype prior to tumor formation. Proc Natl Acad Sci. 2004, 101: 10721-10725. 10.1073/pnas.0403888101.View ArticlePubMedPubMed CentralGoogle Scholar
- Malins DC, Gilman NK, Green VM, Wheeler TM, Barker EA, Anderson KM: A cancer DNA phenotype in healthy prostates, conserved in tumors and adjacent normal cells, implies a relationship to carcinogenesis. Proc Natl Acad Sci. 2005, 102: 19093-19096. 10.1073/pnas.0509630102.View ArticlePubMedPubMed CentralGoogle Scholar
- Galon J, Pagès F, Marincola FM, Thurin M, Trinchieri G, Fox BA, Gajewski TF, Ascierto PA: The immune score as a new possible approachfor the classification of cancer. J Transl Med. 2012, 3 (10): 1-View ArticleGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/13/258/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.